Morningstar's assessment on the cash position from their last assessment 2 months ago:
"Avita is in a healthy financial position and held USD 66 million in cash and no debt as at Sept. 30, 2020. We forecast the company to report a loss of USD 28 million in fiscal 2021, reducing to USD 14 million in fiscal 2022, before positing a USD 5 million profit in fiscal 2023 alongside positive free cash flow. As such, we do not forecast it to require additional funding or experience any financial distress."
- Forums
- ASX - By Stock
- AVH
- Ann: Preliminary Fiscal Second Quarter 2021 Results
Ann: Preliminary Fiscal Second Quarter 2021 Results, page-8
-
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
|
|||||
Last
$2.76 |
Change
0.130(4.94%) |
Mkt cap ! $187.9M |
Open | High | Low | Value | Volume |
$2.74 | $2.77 | $2.66 | $1.044M | 382.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 980 | $2.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.76 | 10173 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 980 | 2.740 |
3 | 36189 | 2.700 |
1 | 10000 | 2.680 |
3 | 2022 | 2.630 |
1 | 2671 | 2.620 |
Price($) | Vol. | No. |
---|---|---|
2.760 | 10173 | 2 |
2.770 | 17029 | 3 |
2.780 | 1500 | 1 |
2.790 | 3162 | 1 |
2.800 | 2372 | 3 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online